Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on December 2, 2024, the Compensation Committee of Taysha's Board of Directors granted one new employee an option to purchase 152,000 shares of the Company's common stock in connection with their employment. The stock option was granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individual entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).
達拉斯，2024年12月6日（全球新聞網絡）—— Taysha Gene Therapies, Inc.（納斯達克：TSHA）（Taysha或公司）是一家臨床階段的生物技術公司，專注於推進基於腺病毒（AAV）的基因療法，以治療中樞神經系統（CNS）嚴重單基因疾病。今天宣佈，在2024年12月2日，Taysha董事會的薪酬委員會授予了一名新員工一個購買152,000股公司普通股的期權，作爲其就業的關聯獎勵。該股票期權是根據Taysha Gene Therapies, Inc. 2023誘導計劃授予的，作爲該個人入職Taysha的誘導材料，符合納斯達克上市規則5635(c)(4)。
The stock option has an exercise price of $3.08 which is equal to the closing price of Taysha's common stock on the date of grant. The stock option has a 10-year term and will vest over four years, with 25% of the option vesting on the first anniversary of the vesting commencement date and the remaining 75% of the option vesting in equal monthly installments over the 36 months thereafter. Vesting of the stock option is subject to such employee's continued service to Taysha on each vesting date.
該股票期權的行使價格爲3.08美元，等於授予日期Taysha普通股的收盤價。該股票期權的有效期爲10年，將在四年內分期歸屬，其中25%的期權將在歸屬開始日期的第一個週年日歸屬，其餘75%的期權將在接下來的36個月內按月等額歸屬。股票期權的歸屬需持續爲Taysha工作的員工在每個歸屬日期完成。
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company's management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit
關於Taysha Gene Therapies
Taysha Gene Therapies（納斯達克：TSHA）是一家臨床階段的生物技術公司，專注於推進基於腺病毒（AAV）的基因療法，以治療中樞神經系統的嚴重單基因疾病。其主導臨床項目TSHA-102正在開發用於萊特綜合徵，這是一種罕見的神經發育障礙，目前尚無批准的能改變疾病基因根源的疾病修飾療法。Taysha專注於開發變革性的藥物，旨在解決嚴重未滿足的醫療需求，顯著改善患者及其護理者的生活。公司的管理團隊在基因治療開發和商業化方面擁有豐富的經驗。Taysha利用這段經驗、其製造過程以及經過臨床和商業驗證的AAV9外殼，努力將治療方案快速從實驗室轉化爲臨床應用。有關更多信息，請訪問
Company Contact:
Hayleigh Collins
Director, Head of Corporate Communications and Investor Relations
Taysha Gene Therapies, Inc.
hcollins@tayshagtx.com
公司聯繫:
Hayleigh Collins
董事，企業傳播和投資者關係負責人
Taysha Gene Therapies, Inc.
hcollins@tayshagtx.com
Media Contact:
Carolyn Hawley
Inizio Evoke
Carolyn.hawley@inizioevoke.com
媒體聯繫人：
Carolyn Hawley
Inizio Evoke
Carolyn.hawley@inizioevoke.com
Source: Taysha Gene Therapies, Inc.
來源：Taysha Gene Therapies, Inc.